Shares of Dexcom (NASDAQ:DXCM) were negative Friday after the company released third-quarter results that beat analysts’ expectations but showed a decline in U.S. revenue year over year.
Earnings per share proved to be 45 cents adjusted vs. 43 cents expected, while revenue came in at $994 million vs. $990 million expected
The company’s revenue increased 2% to $994.2 million from $975 million a year earlier. Dexcom’s U.S. revenue declined 2% from $713.6 million the prior year. The company reported net income of $134.6 million, or 34 cents per share, up from $120.7 million, or 29 cents per share, in the same period last year.
Dexcom offers a suite of tools such as continuous glucose monitors, or CGMs, for patients who have been diagnosed with diabetes. In August, it launched its first over-the-counter product called Stelo, which is intended for adults who do not take insulin.
The company maintained its full fiscal-year guidance and expects revenue of $4 billion to $4.05 billion. Last quarter, Dexcom lowered its guidance from the $4.20 billion to $4.35 billion it forecast in the first quarter.
The company also announced Teri Lawver, Dexcom’s chief commercial officer, will retire at the end of the year. Lawver will stay on as an advisor through early next year, and Sayer will lead the commercial organization as Dexcom searches for a replacement.
DXCM shares fell $1.92, or 2.6%, to $72.92.
Related Stories
